Takei Masao, Tachikawa Eiichi, Hasegawa Hideo, Lee Je-Jung
Division of Cellular Allergology, Research Center Borstel, Parkallee 22 D-23845, Germany.
Biochem Pharmacol. 2004 Aug 1;68(3):441-52. doi: 10.1016/j.bcp.2004.04.015.
Ginseng is a medicinal herb widely used in Asian countries, and many of its pharmacological actions are attributed to the ginsenosides. Dendritic cells (DCs) play a pivotal in the initiation of T-cell-mediated immune responses, making them an attractive cellular adjuvant for use in cancer vaccines. In this study, we investigated whether M1 and M4, end products of steroidal ginseng saponins metabolized in digestive tracts, can drive DCs maturation from human monocytes in vitro. Human monocytes were cultured with GM-CSF and IL-4 for 6 days, followed by another 2 days in the presence of M1, M4 or TNF-alpha as a maturation stimulus. Stimulation with 20 microM of M1 or M4 increased expression level of CD80, CD83 and CD86 as expressed by mean fluorescence intensity (MFI) and decreased endocytic activity. M4-primed mature DCs also displayed enhanced T cells stimulatory capacity in a MLR, as measured by T cell proliferation. Mature DCs differentiated with M1 or M4 induced the differentiation of naïve T cells towards a helper T cell type 1 (Th1) response at DC/T (1:5) cells ratio depending on IL-12 secretion. In CTL assay, the production of IFN-gamma and 51Cr release on M4-primed mature DCs was more augmented than of immature DCs or TNF-alpha-primed mature DCs. These results suggest that M4 may be used on DC-based vaccines for cancer immunotherapy.
人参是一种在亚洲国家广泛使用的草药,其许多药理作用都归因于人参皂苷。树突状细胞(DCs)在T细胞介导的免疫反应启动中起关键作用,使其成为癌症疫苗中一种有吸引力的细胞佐剂。在本研究中,我们调查了在消化道中代谢的甾体人参皂苷的终产物M1和M4是否能在体外驱动人单核细胞来源的DCs成熟。将人单核细胞与GM-CSF和IL-4培养6天,然后在M1、M4或TNF-α作为成熟刺激物存在的情况下再培养2天。用20微摩尔的M1或M4刺激可增加平均荧光强度(MFI)所表示的CD80、CD83和CD86的表达水平,并降低内吞活性。经M4预处理的成熟DCs在混合淋巴细胞反应(MLR)中也表现出增强的T细胞刺激能力,通过T细胞增殖来衡量。用M1或M4分化的成熟DCs在DC/T(1:5)细胞比例下,根据IL-12的分泌情况,诱导初始T细胞向辅助性T细胞1型(Th1)反应分化。在细胞毒性T淋巴细胞(CTL)试验中,经M4预处理的成熟DCs上IFN-γ的产生和51Cr的释放比未成熟DCs或经TNF-α预处理的成熟DCs更增强。这些结果表明,M4可用于基于DC的癌症免疫治疗疫苗。